Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL
Refinitiv1분 미만 읽기
Genmab A/S GMAB:
GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
GENMAB - FDA HAS ACCEPTED FOR PRIORITY REVIEW NEW SBLA FOR EPCORITAMAB PLUS R(2), WITH ACTION DATE OF NOVEMBER 30
이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오